Purchase Summary

In order to access content on the FENIX Marketplace, you must have an account. You will also have access to FENIX Free updates.

The price for access is $599.00.


Account Information Already have an account? Log in here

*
LEAVE THIS BLANK

Payment Information We Accept Visa, Mastercard, American Express and Discover

 

By selecting this, I agree to receive emails from fenix.group.


You will be redirected to view the full article after purchasing. You will receive your account and payment information in a confirmation email, and can be viewed at any time in your Account.

JNJ BCMA CAR-T, JNJ-4528, US filing on track for YE 2020, but EU delayed to H1 2021; JNJ Q2 2020 earnings call

Here is a brief preview of this blast: Thursday, 16 July, JNJ held their Q2 2020 earnings call (press release / slides). The company confirmed that filing of their BCMA CAR-T for multiple myeloma, JNJ-4528 (cilta-cel), remains on track for YE 2020 in the US. However, EU filing has been pushed back slightly to early 2021 (from YE 2020). Meanwhile, despite the impact of COVID-19, JNJ reported double-digit QoQ growth of its multiple myeloma blockbuster, Darzalex (US +33%; WW +16%). Below, Celltelligence provides further context on JNJ-4528 and how Darzalex’s sales resilience could help support continued CAR-T development and future commercialization.

About The Author

Matthew Maryniak

|
President of Fenix Group International
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.